Skip to main content
. 2017 Dec 7;9(2):241–252. doi: 10.1111/1759-7714.12570

Figure 3.

Figure 3

Kaplan–Meier survival estimate. Cisplatin‐based platinum‐pemetrexed (PP) doublets: (a) progression‐free survival (PFS) and (b) overall survival. Carboplatin‐based PP doublets: (c) PFS and (d) OS. Cisplatin‐based versus carboplatin‐based PP doublets: (e) PFS and (f) OS.